Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 8INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 3Gastrointestinal 2

Conditions

Thromboembolism 1Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Pancreatic Ductal 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 216Irinotecan 185Cisplatin 143Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 41Cyclophosphamide 39trifluridine tipiracil drug combination 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Enoxaparin × Gastrointestinal × Clear all
NCT02444572 2021-07-29

ENOXACARE

Les Laboratoires des Médicaments Stériles

Phase 4 Completed
168 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Thromboembolism

NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 2 Completed
279 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡